Actively Recruiting
Phase II Study of Hypofractionated Radiation Therapy to Treat Merkel Cell Carcinoma
Led by M.D. Anderson Cancer Center · Updated on 2026-07-16
52
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating hypofractionated radiation therapy for patients with Merkel cell carcinoma, a rare type of skin cancer. This phase II trial aims to estimate the 2-year local and nodal control rates after delivering radiation to the primary tumor site and nearby lymph nodes. The study also tracks outcomes like recurrence, metastasis, survival rates, and radiation-related side effects. Participants receive radiation therapy in 10 daily doses from Monday to Friday over 2 weeks. This higher dose in a shorter time aims to be more convenient and potentially less harmful to the immune system. Radiation targets the original tumor area and lymph nodes that may contain cancer cells. Immunotherapy can be given before, during, or after radiation if needed. During the study, participants undergo clinical exams and imaging to check for cancer control and side effects. Researchers measure disease recurrence, survival, and radiation toxicity over an average of 2 years. Participants must use contraception due to radiation risks and will be monitored regularly. The total participation time varies but includes follow-up to assess long-term outcomes and safety.
CONDITIONS
Brief Title
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Research Team
D
Devarati Mitra
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here